Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

NCT01260506 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma Multiforme

Interventions

DRUG: VB-111
DRUG: Bevacizumab

Sponsor

Vascular Biogenics Ltd. operating as VBL Therapeutics